title: Weekly systemic cisplatin plus locoregional hyperthermia: an effective treatment for patients with recurrent cervical carcinoma in a previously irradiated area.
abstract: OBJECTIVE
  Patients with recurrent cervical carcinoma within a previously irradiated area respond poorly to chemotherapy. We have treated these patients with simultaneous cisplatin and hyperthermia (CDDP + HT) and investigated response, toxicity, palliative effect and survival.
  
  
  METHODS
  Between 1992 and 2005 47 patients received CDDP + HT. Response was evaluated by gynaecologic examination and CT-scan. The Common Toxicity Criteria (CTC) were used for evaluation of toxicity and palliative effect. The Kaplan-Meier method was used to estimate survival, and Cox regression analysis to evaluate the influence of prognostic factors.
  
  
  RESULTS
  The objective response rate was 55%, palliation was achieved in 74% and operability in 19% of patients. Two patients are currently disease free at 9 years and 18 + months following treatment and 2 remained disease free until death by other causes. The median survival was 8 months and was influenced by duration of disease free interval and tumour diameter. Grade 3-4 haematological toxicity was observed in 36% of patients and renal toxicity was maximum grade 2.
  
  
  CONCLUSIONS
  CDDP + HT results in a high response rate and acceptable toxicity in patients with recurrent cervical cancer.
authors: Department of Radiation Oncology, Hyperthermia Unit, Shahrekord University of Medical Sciences, Shahrekord, Iran. m.franckena@erasmusmc.nl
authors: Martine
authors: M
authors: Franckena
authors: Ronald
authors: R
authors: De Wit
authors: Anca C
authors: AC
authors: Ansink
authors: Annelise
authors: A
authors: Notenboom
authors: Richard A M
authors: RA
authors: Canters
authors: Daryoush
authors: D
authors: Fatehi
authors: Gerard C
authors: GC
authors: Van Rhoon
authors: Jacoba
authors: J
authors: Van Der Zee
mesh_terms: D000328:Adult; D000368:Aged; D000970:Antineoplastic Agents / Q000008:administration & dosage*; D002945:Cisplatin / Q000008:administration & dosage*; D003131:Combined Modality Therapy; D004305:Dose-Response Relationship, Drug; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D006979:Hyperthermia, Induced / Q000379:methods*; D053208:Kaplan-Meier Estimate; D008137:Longitudinal Studies; D008875:Middle Aged; D009364:Neoplasm Recurrence, Local / Q000517:prevention & control; D010166:Palliative Care; D012044:Regression Analysis; D016879:Salvage Therapy; D015996:Survival Rate; D016896:Treatment Outcome; D002583:Uterine Cervical Neoplasms / Q000628:therapy*
chemical_list: D000970:Antineoplastic Agents; D002945:Cisplatin